Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 4/20 | 0.46 |
| ▸ | ICMT | O60725 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 5/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3869461 | 0.91 | MME (0.41) | ACEPPARAC3AR1MMEALOX5 | |
| SCHEMBL3869463 | 0.91 | MME (0.41) | ACEPPARAC3AR1MMEALOX5 | |
| SCHEMBL3869501 | 0.88 | ACE (0.47) | ACEICMTTDP1PPARAC3AR1 | |
| SCHEMBL4823549 | 0.88 | ACE (0.47) | ACEICMTTDP1PPARAC3AR1 | |
| SCHEMBL4826295 | 0.88 | C3AR1 (0.49) | ACEICMTTDP1PPARAC3AR1 | |
| SCHEMBL3869641 | 0.88 | C3AR1 (0.49) | ACEICMTTDP1PPARAC3AR1 | |
| SCHEMBL4825384 | 0.88 | ACE (0.44) | ACEICMTTDP1PPARAC3AR1 | |
| SCHEMBL3871885 | 0.88 | ACE (0.44) | ACEICMTTDP1PPARAC3AR1 | |
| SCHEMBL3863460 | 0.87 | C3AR1 (0.48) | ACEICMTTDP1PPARAC3AR1 | |
| SCHEMBL4818632 | 0.87 | C3AR1 (0.48) | ACEICMTTDP1PPARAC3AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7358248-B2 | Substituted amino carboxylic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC (US) | 2008-04-15 | — | — | US | claimed |
| US-20040266789-A1 | Substituted amino carboxylic acids | INSTITUTE FOR DIABETES DISCOVERY, L.L.C. | 2004-12-30 | — | — | US | claimed |
| US-7498356-B2 | Substituted amino carboxylic acids | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY LLC (US) | 2009-03-03 | — | — | US | disclosed |
| US-7358248-B2 | Substituted amino carboxylic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC (US) | 2008-04-15 | — | — | US | disclosed |
| EP-1814869-A2 | SUBSTITUTED AMINO ACIDS AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS | The Institutes for Pharmaceutical Discovery, LLC (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060122223-A1 | Substituted amino carboxylic acids | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC | 2006-06-08 | — | — | US | disclosed |
| WO-2006055725-A2 | SUBSTITUTED AMINO ACIDS AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2006-05-26 | — | — | WO | disclosed |
| US-20040266789-A1 | Substituted amino carboxylic acids | INSTITUTE FOR DIABETES DISCOVERY, L.L.C. | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122223-A1 | Substituted amino carboxylic acids | PTPRS, PTPRO, PTPRJ | ACE 978/4885ICMT 4335/4885TDP1 1238/4885 |
| US-20040266789-A1 | Substituted amino carboxylic acids | PTPRS, PPM1B, PTPRO | ACE 1006/4885ICMT 4431/4885TDP1 744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.